University of Massachusetts Medical School

What University of Massachusetts Medical School does

UMass Chan Medical School (University of Massachusetts Chan Medical School) is the commonwealth of Massachusetts's public academic health sciences center, founded in 1962 in Worcester, MA, and a component of the University of Massachusetts system. The institution operates three graduate schools: the T.H. Chan School of Medicine (175 MDs per cohort), the Morningside Graduate School of Biomedical Sciences, and the Tan Chingfen Graduate School of Nursing, collectively enrolling 1,400+ students, with 270+ degrees awarded at the 2026 commencement. Its research enterprise spans 500+ active clinical trials and is anchored by the RNA Therapeutics Institute, Gene Therapy Center, and Horae Gene Therapy Center, supported by approximately $305 million in federal and private research funding in FY2025 ($190.4M NIH, 345 awards) and historically $1.7 billion in NIH funding over the past decade.

The technology and commercial footprint includes two wholly owned operating divisions: MassBiologics, the only nonprofit FDA-licensed manufacturer of vaccines, biologics, and viral vector gene therapies in the United States (Boston and Fall River, MA facilities), and ForHealth Consulting, a public service health care consulting operation. The institution derives revenue from federal and private research grants (~$305M annually), tuition across three schools, contract manufacturing services through MassBiologics to enterprise clients including Merck (bezlotoxumab/Zinplava), PTC Therapeutics (Upstaza), SparingVision, and the Serum Institute of India (Rabishield), and philanthropy (including a $175M Morningside Foundation gift in 2021, a $35M DiMare Foundation gift in 2024-2025, and a $500M Advancing Together campaign).

The institution's go-to-market operates across four customer segments: prospective medical, biomedical, and nursing students; clinical trial volunteers enrolled through the Conquering Diseases platform; biopharmaceutical industry partners served by MassBiologics CMO services; and donors/foundations supporting research and education. The school markets through its website, six social media channels (Facebook, Twitter/X, YouTube, Instagram, LinkedIn, Bluesky), email newsletters, virtual campus tours, and earned media coverage in outlets including The New York Times, Boston Globe, and STAT. Geographic reach is primarily Massachusetts (Worcester, Springfield, Burlington) with global clinical and manufacturing partnerships; revenue concentration is high in NIH/federal research funding, which Chancellor Collins has publicly identified as currently disrupted.

Name

University of Massachusetts Medical School

Legal name

University of Massachusetts Chan Medical School

Website

https://umassmed.edu

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

UMass Chan Medical School is the University of Massachusetts system's public academic health sciences center in Worcester, MA, operating three graduate schools (T.H. Chan School of Medicine, Morningside GSBS, Tan Chingfen GSN), $305M in annual research funding, and MassBiologics, the only nonprofit FDA-licensed vaccine and biologics manufacturer in the U.S.

Ownership category

akta.pro rank

Product category

Academic Medical Center / Biomedical Research Institution

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Medical education
• Biomedical research
• Biologics manufacturing
• Gene therapy research
• Graduate nursing programs

Headquarters

HQ city

Worcester

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Research Funding: UMass Chan Medical School receives approximately $305 million in federal and private research funding annually (fiscal year 2025). NIH funding totaled $190.4 million in fiscal year 2025. Research funding supports the institution's basic, clinical, and translational science programs across multiple disease areas.
2. Tuition and Fees: Revenue from tuition and fees for the T.H. Chan School of Medicine, Morningside Graduate School of Biomedical Sciences, and Tan Chingfen Graduate School of Nursing. In-state and out-of-state tuition applies; financial aid and scholarships are available.
3. MassBiologics Biologics Manufacturing: MassBiologics generates revenue through contract manufacturing organization (CMO) services including development services, cGMP manufacturing, quality services, and viral vector therapeutics for external clients. The unit is the only nonprofit FDA-licensed manufacturer of vaccines and biologics in the United States.
4. Philanthropy and Fundraising: The Advancing Together campaign seeks to raise $500 million for innovation, discoveries, and education. Major gifts include a $175 million gift from The Morningside Foundation (2021) and a $35 million gift from the Paul J. DiMare Foundation.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

UMass Chan Medical School is a public academic health sciences center that delivers graduate-level medical, biomedical science, and nursing education through three graduate schools, conducts biomedical and translational research across RNA therapeutics, gene therapy, immunology, neuroscience, and cancer biology, and operates MassBiologics — the only nonprofit FDA-licensed vaccine and biologics manufacturer in the United States — providing contract manufacturing and viral vector gene therapy production. Additional offerings include 500+ active clinical trials managed through the Conquering Diseases platform and public-service health care consulting via ForHealth Consulting.

Product overview

UMass Chan Medical School is an academic health sciences center comprising three graduate schools (T.H. Chan School of Medicine, Morningside Graduate School of Biomedical Sciences, and Tan Chingfen Graduate School of Nursing), a nonprofit FDA-licensed biologics manufacturer (MassBiologics), a public service consulting division (ForHealth Consulting), and numerous research centers including the RNA Therapeutics Institute and Horae Gene Therapy Center. The institution also operates Conquering Diseases, a clinical trial management platform. Primary offerings are graduate-level medical, scientific, and nursing education, biomedical research, and biologics manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• T.H. Chan School of Medicine: One of three graduate schools at UMass Chan; medical school ranked first in Massachusetts for primary care education
• Morningside Graduate School of Biomedical Sciences
• Tan Chingfen Graduate School of Nursing
• MassBiologics
• ForHealth Consulting

Products and services

• T.H. Chan School of Medicine (MD, MD/PhD, MD/MBA Programs) Graduate-level medical education program offering MD, MD/PhD, and accelerated MD/MBA tracks, ranked #1 in Massachusetts for primary care education with 175 students per cohort and emphasis on primary care specialties and public sector practice.
• Morningside Graduate School of Biomedical Sciences (PhD and MS Programs) Graduate-level biomedical research training offering PhD and MS programs across 11 program areas including biochemistry, cancer biology, neuroscience, RNA therapeutics, and immunology; PhD students typically receive full tuition and stipend funding.
• Tan Chingfen Graduate School of Nursing (DNP, MSN, PhD Programs) Graduate nursing education offering master's, post-master's, and doctoral degrees preparing nurse practitioners, nurse educators, nurse scientists, and nursing leaders; DNP program ranked 29th nationally and includes a direct entry MS option for non-nurses running approximately 16 months.
• MassBiologics Contract Manufacturing Services FDA-licensed nonprofit contract manufacturing organization providing biologics and vaccine manufacturing services including development, non-GMP monoclonal antibody production, cGMP manufacturing, aseptic fill and finish, quality services, and viral vector therapeutics to biotech and pharma clients.
• ForHealth Consulting Public service consulting and operations division of UMass Chan Medical School providing health care consulting services to external organizations.
• Conquering Diseases Clinical Trial Platform Web-based platform enabling volunteer screening and enrollment in UMass Chan's 500+ active clinical trials covering cancer, ALS, stroke, muscular dystrophy, infectious diseases, lupus, and multiple sclerosis.

Quantifiable outcome

• 35% of MD graduates enter primary care residencies (61 students in 2026 class)
• +4 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered minor, core and major.

• Worcester State UniversityminorStrategic or Co-development Partner · 21 June 2026Researchers from Worcester State University, UMass Chan Medical School, and Harvard Medical School conducted a qualitative study on an Acceptance and Commitment Therapy (ACT) group-based intervention called ACT-PAC for parents of youth with anxiety disorders.
• Harvard Medical SchoolminorStrategic or Co-development Partner · 21 June 2026Harvard Medical School collaborated with UMass Chan and Worcester State University researchers on a qualitative study of the ACT-PAC intervention for parents of youth with anxiety disorders.
• Trenchant BioSystemscoreStrategic or Co-development Partner · 31 March 2026Partnership between Trenchant BioSystems, UMass Chan Medical School, and Caring Cross to develop an automated manufacturing platform for gene-modified hematopoietic stem cell (HSC) therapies targeting sickle cell disease and beta thalassemia. The collaboration leverages Trenchant BioSystems' AutoCell platform using microbubble separation technology to reduce footprint and costs compared to conventional methods. The alliance plans to seek FDA feedback through an INTERACT meeting in Q1 2027 and launch a Phase I/II clinical trial later that year.
• Caring CrosscoreStrategic or Co-development Partner · 31 March 2026Caring Cross collaborated with Trenchant BioSystems and UMass Chan to develop automated manufacturing for gene-modified HSC therapies for sickle cell disease and beta thalassemia, contributing expertise in cell and gene therapy development and clinical translation.
• Magnus MedicalcoreStrategic or Co-development Partner · 5 February 2026Magnus Medical partnered with UMass Chan for its $11.6 million DoD-funded pivotal clinical trial evaluating SAINT neuromodulation therapy for postpartum depression. UMass Chan is one of four research institutions enrolled in this randomized controlled trial, led nationally by Magnus Medical. SAINT is already FDA-cleared for major depressive disorder.
• SparingVisionmajorStrategic or Co-development Partner · 13 October 2025MassBiologics of UMass Chan announced partnership with SparingVision to manufacture gene therapy for ocular disease. MassBiologics provides its FDA-licensed cGMP manufacturing capabilities for the production of SparingVision's gene therapy product.
• Baylor College of MedicineminorStrategic or Co-development Partner · 4 April 2025Researchers from Baylor College of Medicine, The Jackson Laboratory, and University of Massachusetts Medical School developed a detailed atlas of AAV viral tissue targeting to enhance gene therapy precision. The atlas maps how 10 AAV variants interact with 22 tissues in mice, revealing unique properties of AAV4 in targeting endothelial cells and pancreatic beta cells.
• The Jackson LaboratoryminorStrategic or Co-development Partner · 4 April 2025The Jackson Laboratory collaborated with Baylor College of Medicine and UMass Chan to create an AAV tissue targeting atlas for gene therapy precision, mapping AAV variant interactions with mouse tissues.
• Mass General BrighamminorStrategic or Co-development Partner · 3 April 2025Mass General Brigham collaborated with UMass Chan on studies of 'skilled nursing facility at home' care models, investigating intensive care at home as an alternative to hospital discharge delays.
• Lahey Hospital & Medical Center (Beth Israel Lahey Health)majorStrategic or Co-development Partner · 1 January 2023UMass Chan-Lahey regional campus established in Burlington, MA, as a second regional campus with Lahey Hospital & Medical Center, part of Beth Israel Lahey Health, to expand medical education in the northeastern part of Massachusetts.
• PTC TherapeuticsmajorStrategic or Co-development Partner · 1 September 2020MassBiologics partnered with PTC Therapeutics to manufacture gene therapy for a rare pediatric condition. The European Commission subsequently granted marketing authorization for Upstaza (eladocagene exuparvovec) for AADC deficiency, a rare genetic disorder.
• Serum Institute of IndiamajorStrategic or Co-development Partner · 1 October 2017Serum Institute of India launched Rabishield (rabies monoclonal antibody), developed in partnership with MassBiologics. This partnership leverages MassBiologics' expertise in monoclonal antibody development and Serum Institute's global manufacturing and distribution scale.
• Baystate HealthmajorStrategic or Co-development Partner · 1 January 2015UMass Chan-Baystate regional campus established in Springfield, MA, extending the T.H. Chan School of Medicine's educational programs to the western part of Massachusetts through a partnership with Baystate Health.

Scale indicators19 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Harvard Medical School: Harvard Medical School is the leading Boston-area peer for medical education, NIH-funded biomedical research, and academic medical center operations. It is highly comparable to UMass Chan in geographic market, research enterprise scale, and graduate program depth, and competes directly for faculty, students, and NIH funding.
• Boston University Chobanian & Avedisian School of Medicine: BU's medical school is a comparable urban research-intensive medical school in Boston with overlapping NIH funding sources and similar primary care and research missions. It competes directly with UMass Chan for graduate students, faculty, and clinical research collaborations in the same metro.
• Tufts University School of Medicine: Tufts is a Boston-area peer medical school with overlapping MD, biomedical PhD, and public health programs. It is comparable in scale of research funding and competes with UMass Chan for graduate applicants, NIH grants, and clinical partnerships in the New England market.
• Yale School of Medicine: Yale is a New England peer medical school with a comparable mix of NIH-funded biomedical research, MD and PhD programs, and an academic medical center. It competes with UMass Chan for top-tier faculty, research funding rankings, and graduate students in biomedical sciences.
• Brown University Warren Alpert Medical School: Brown's medical school is a regional peer with an MD program and significant biomedical research portfolio anchored in Providence, RI. It is comparable in primary care orientation and competes for graduate applicants and NIH funding in the broader New England market.

Broad incumbents

• Johns Hopkins School of Medicine: Johns Hopkins is a larger, established national peer with a substantially larger research enterprise and academic medical center footprint. It is comparable in biomedical research depth and NIH ranking position, and serves as a benchmark for UMass Chan's research scale and prestige.
• Stanford University School of Medicine: Stanford is a top-tier peer medical school with comparable RNA biology and gene therapy research strength, alongside a much larger overall research enterprise. It competes with UMass Chan in the same molecular medicine and RNA therapeutics talent market.
• University of Pennsylvania Perelman School of Medicine: Penn Medicine is a large research-intensive peer medical school with comparable gene therapy, immunology, and biomedical research depth, plus a strong academic medical center. It benchmarks UMass Chan on NIH funding scale and graduate program rankings.
• University of Michigan Medical School: Michigan is a large public peer medical school with substantial NIH funding, MD/PhD programs, and biomedical research breadth. It is comparable to UMass Chan as a public medical school with strong primary care and research missions and provides a relevant benchmark for public-medical-school economics.

Emerging players

• Geisinger Commonwealth School of Medicine: Geisinger Commonwealth is a smaller, emerging medical school focused on community-based primary care education. It shares UMass Chan's primary care mission but operates at a smaller scale with less research intensity, making it a comparable but emerging peer for community-oriented medical education.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/umasschan
• YouTubeyoutube.com/c/UMassChanMedicalSchool
• Facebookfacebook.com/109315172443950
• LinkedInlinkedin.com/school/umasschan
• Instagraminstagram.com/umasschan

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University of Massachusetts Medical School